Literature DB >> 14871297

Decreased CD4+CD25+ T cells in peripheral blood of patients with systemic lupus erythematosus.

M-F Liu1, C-R Wang, L-L Fung, C-R Wu.   

Abstract

Recent animal studies have shown that CD4+CD25+ T cells play a crucial role in the suppression of the immune response and that depletion of this subset of T cells might lead to development of autoimmune diseases. The aim of the present study was to investigate the levels of CD4+CD25+ T cells in the peripheral blood of patients with systemic lupus erythematosus (SLE). Ninety-four SLE patients, 52 patients with rheumatoid arthritis (RA) and 50 age- and gender-matched healthy individuals were enrolled in the study. A flowcytometric method was applied in the measurement of CD4+CD25+ T cells. The results showed that patients with SLE had statistically lower levels of CD4+CD25+ T cells than did normal controls, when expressed as either percentages of peripheral blood mononuclear cells (PBMCs) (mean +/- SD, 8.49 +/- 6.36 versus 11.11 +/- 4.58%, P < 0.05) or absolute cell numbers (98.77 +/- 97.52 versus 213.93 +/- 104.52 cells/mm3, P < 0.05). In terms of CD25brightCD4+ T cells, defined as having a fluorescence intensity of CD25 expression exceeding 100, SLE patients still had significantly lower levels than did normal controls expressed as percentages of PBMCs (1.76 +/- 1.32 versus 3.73 +/- 1.30%, P < 0.05). No significant differences could be found between RA patients and normal controls. The overwhelming majority of CD4+CD25+ T cells belonged to CD45RO+ cells and most did not express the CD69 molecule. Although decreased CD4+CD25+ T cells were found in SLE patients, we failed to find a significant correlation between the levels of CD4+CD25+ T cells and disease activities of SLE. To the best of our knowledge, this is the first study to demonstrate that patients with SLE had decreased CD4+CD25+ T cells. However, the exact role of the decreased CD4+CD25+ T cells in the pathogenesis of SLE remains to be elucidated.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14871297     DOI: 10.1111/j.0300-9475.2004.01370.x

Source DB:  PubMed          Journal:  Scand J Immunol        ISSN: 0300-9475            Impact factor:   3.487


  91 in total

1.  Mechanistic target of rapamycin complex 1 expands Th17 and IL-4+ CD4-CD8- double-negative T cells and contracts regulatory T cells in systemic lupus erythematosus.

Authors:  Hiroshi Kato; Andras Perl
Journal:  J Immunol       Date:  2014-03-28       Impact factor: 5.422

2.  Regulatory T cells can migrate to follicles upon T cell activation and suppress GC-Th cells and GC-Th cell-driven B cell responses.

Authors:  Hyung W Lim; Peter Hillsamer; Chang H Kim
Journal:  J Clin Invest       Date:  2004-12       Impact factor: 14.808

3.  Circulating and thymic CD4 CD25 T regulatory cells in myasthenia gravis: effect of immunosuppressive treatment.

Authors:  Andrea Fattorossi; Alessandra Battaglia; Alexia Buzzonetti; Francesca Ciaraffa; Giovanni Scambia; Amelia Evoli
Journal:  Immunology       Date:  2005-09       Impact factor: 7.397

4.  Anti-CD3 antibody therapy attenuates the progression of hypertension in female mice with systemic lupus erythematosus.

Authors:  Keisa W Mathis; Erin B Taylor; Michael J Ryan
Journal:  Pharmacol Res       Date:  2017-04-08       Impact factor: 7.658

Review 5.  T lymphocytes in Sjögren's syndrome: contributors to and regulators of pathophysiology.

Authors:  Gikas E Katsifis; Niki M Moutsopoulos; Sharon M Wahl
Journal:  Clin Rev Allergy Immunol       Date:  2007-06       Impact factor: 8.667

Review 6.  The role of CD4+CD25+ T regulatory cells in autoimmune diseases.

Authors:  E Toubi
Journal:  Clin Rev Allergy Immunol       Date:  2008-06       Impact factor: 8.667

7.  Decrease of regulatory T cells in patients with systemic lupus erythematosus.

Authors:  S Mellor-Pita; M J Citores; R Castejon; P Tutor-Ureta; M Yebra-Bango; J L Andreu; J A Vargas
Journal:  Ann Rheum Dis       Date:  2006-04       Impact factor: 19.103

8.  Regulatory T cells in patients with inflammatory bowel diseases treated with adacolumn granulocytapheresis.

Authors:  Emilio Cuadrado; Marta Alonso; Maria-Dolores de Juan; Pilar Echaniz; Juan-Ignacio Arenas
Journal:  World J Gastroenterol       Date:  2008-03-14       Impact factor: 5.742

9.  Assay of T- and NK-cell subsets and the expression of NKG2A and NKG2D in patients with new-onset systemic lupus erythematosus.

Authors:  Wen-Xian Li; Hai-Feng Pan; Jian-Li Hu; Chang-Zhong Wang; Ning Zhang; Jing Li; Xiang-Pei Li; Jian-Hua Xu; Dong-Qing Ye
Journal:  Clin Rheumatol       Date:  2009-12-10       Impact factor: 2.980

10.  Altered T-cell subtypes in spondyloarthritis, rheumatoid arthritis and polymyalgia rheumatica.

Authors:  Christian Dejaco; Christina Duftner; Andrea Klauser; Michael Schirmer
Journal:  Rheumatol Int       Date:  2009-05-15       Impact factor: 2.631

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.